SCHEMBL2565733

SCHEMBL2565733

CCc1c(C(=O)OC)noc1CC(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.36
LMNA P02545 4/20 0.36
RAB9A P51151 2/20 0.36
ALDH1A1 P00352 6/20 0.33
KDM4E B2RXH2 3/20 0.33
MAPT P10636 3/20 0.33
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
GAA P10253 1/20 0.33
S1PR1 P21453 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
MAPK1 P28482 2/20 0.32
GMNN O75496 1/20 0.32
CYP1A2 P05177 1/20 0.32
POLB P06746 1/20 0.32
CYP3A4 P08684 1/20 0.32
GABRA1 P14867 1/20 0.32
TSHR P16473 1/20 0.32
GABRG2 P18507 1/20 0.32
NFKB1 P19838 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2569102 0.88 S1PR1 (0.37) NPSR1LMNARAB9AALDH1A1KDM4E
SCHEMBL16301189 0.87 LMNA (0.35) NPSR1LMNARAB9AALDH1A1KDM4E
SCHEMBL2570427 0.82 RAB9A (0.35) NPSR1LMNARAB9AALDH1A1KDM4E
SCHEMBL12000503 0.81 NPSR1 (0.38) NPSR1LMNARAB9AALDH1A1KDM4E
SCHEMBL1226715 0.80 NPSR1 (0.37) NPSR1LMNARAB9AALDH1A1KDM4E
SCHEMBL1225848 0.77 S1PR1 (0.37) NPSR1LMNAALDH1A1KDM4EKMT2A
SCHEMBL9428201 0.72 NPSR1 (0.42) NPSR1LMNAALDH1A1GAAMAPK1
SCHEMBL2565404 0.71 GRIA1 (0.43) RAB9AALDH1A1GAAS1PR1MAPK1
SCHEMBL13285297 0.70 S1PR1 (0.36) LMNARAB9AALDH1A1KDM4EMAPT
SCHEMBL16508623 0.69 GRIA1 (0.44) ALDH1A1GAAS1PR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354398-B2 Substituted isoxazole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-15 US disclosed
CN-102361867-A Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases BRISTOL MYERS SQUIBB CO 2012-02-22 CN disclosed
US-20110300165-A1 SUBSTITUTED ISOXAZOLE COMPOUNDS The Board of TRustees of the University of Illinoi University of Illinios (US) 2011-12-08 US disclosed
EP-2382212-A1 SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES Bristol-Myers Squibb Company (US) 2011-11-02 EP disclosed
WO-2010085581-A1 SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110300165-A1 SUBSTITUTED ISOXAZOLE COMPOUNDS S1PR4, S1PR3, S1PR1 NPSR1 218/4885LMNA 3594/4885RAB9A 1417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.